Tyrosinemia type I

MONDO:0010161

Tyrosinemia type 1 (HTI) is an inborn error of tyrosine catabolism caused by defective activity of fumarylacetoacetate hydrolase (FAH) and is characterized by progressive liver disease, renal tubular dysfunction, porphyria-like crises and a dramatic improvement in prognosis following treatment with nitisinone.

Also known as: FAH deficiency, Tyrosinemia Type 1, fumarylacetoacetase deficiency, fumarylacetoacetate hydrolase deficiency, hepatorenal tyrosinemia, type I tyrosinemia, tyrosinemia type I, Fah deficiency

27 clinical trials for this condition and its sub-types.

Follow this condition — get notified about new trials

Broader categories

Sort by